Cibiltech’s flagship product, Predigraft, offers physicians and hospitals an easy-to-use platform that simplifies access to data and decision making. Cibiltech recently announced that the first patient has been enrolled in a prospective randomized controlled trial to assess the use of their iBox technology as an early intervention monitoring tool for kidney transplanted patients.
Cibiltech is a pioneer in the development of artificial intelligence-based software medical devices and their ambition is to build the distribution platform for algorithms to prevent organ failures. Predigraft embeds the iBox algorithm, a unique AI-based technology predicting individual long term kidney allograft survival.
The team recently announced that the first patient has been enrolled in the CIBIL clinical trial “Clinical Impact of the iBox as an early Intervention tool”. A prospective randomized controlled trial to assess the use of a software predicting allograft survival in the follow-up of kidney transplanted patients (NCT05112315). This milestone marks the beginning of this first-of-its-kind clinical trial conducted in Europe evaluating a digital health solution.
Stéphane Tholander, CEO, Cibiltech said: “The CIBIL study aims to provide clinical and health economic evidence to allow further deployment of Predigraft (iBox) in Europe. It paves the way to a large adoption of AI-based medical device softwares. We recently joined the DigitalHealth.London Accelerator programme, and we are looking forward to this tailored support. It could further strengthen our results from the CIBIL trial with real world evidence pilot studies and demonstrate the savings Predigraft could achieve for the NHS by reducing returns to dialysis.”
Find out more here: iBox – Cibiltech
Cibiltech is a member of the sixth cohort of the DigitalHealth.London Accelerator programme.
The DigitalHealth.London Accelerator is a collaborative programme funded by two of London’s Academic Health Science Networks – UCL Partners, and the Health Innovation Network, as well as MedCity, CW+ and receives match funding from the European Regional Development Fund.